SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW.X) is trending as the community rallies behind its fully community-driven nature and cross-chain functionality. Active discussions revolve around its organic growth, deflationary mechanisms, and potential listings on major exchanges. The project's unique branding and engaged community, known as "murders," are also key talking points.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors react to earnings and forward guidance, with debates around whether AI-driven demand justifies the stock's recent surge. Community discussions revolve around gross margins, potential upgrades, and the possibility of a post-earnings pullback after a significant run-up in recent months. Some traders express disappointment in the initial after-hours movement, while others remain optimistic about the company's long-term prospects in the semiconductor industry.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as discussions revolve around its potential in the quantum computing sector, with some traders pointing to a recent analyst upgrade. The community is debating whether the stock is overvalued, citing its high market cap relative to revenue, while others highlight its technological advancements and partnerships. Overall, sentiment is mixed with bullish investors anticipating further gains while bearish traders foresee a significant correction.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending amid speculation of a potential deal with a major player like Oracle, with the community buzzing about SoftBank's existing investment in Cipher Mining potentially facilitating such a partnership. Community members are closely watching for official news, anticipating a significant surge if a deal is confirmed, while also managing expectations of a possible short-term dip if the rumors prove unfounded. The stock's performance is also drawing comparisons to others in the AI and data center space, like IREN, as investors assess its potential for growth.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending due to discussions around its valuation relative to its future potential in the nuclear energy sector, with some community members pointing out the high valuation given its lack of current revenue. The stock's recent groundbreaking on its first Aurora powerhouse is fueling optimism, while others highlight regulatory hurdles and potential insider selling. Options positioning suggests a bullish outlook, although some investors are wary of a potential correction.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the potential impact of a recent purchase order and its implications for future revenue and partnerships. Community members are debating whether the order size justifies the current valuation and speculating on upcoming news, particularly from the CIOE conference. The discussion also involves the company's potential role in the AI sector, with some expressing impatience for further commercial progress.

WTF Opossum is a Meme token on solana Blockchain with utilities and tools for traders and token owners as well. Launched in July 2024. The project built a vote for exposure telegram bot with a leaderboard for tokens on multiple blockchains. The variety of tools contain the voting agent, contract scanner and market details checker. The $WTFO token itself was designed as a unique meme character. An opossum, the symbol of immortals. Just like opossums, WTFO is a surviver, focusing on it's utilities and the fun aspect of communities as being a real meme project.

WTF Opossum

WTF Opossum ($WTFO.X) is gaining attention as community members highlight its burn mechanics, utility, and dedicated development team. Discussions suggest a shift in sentiment towards a long-term investment, supported by its continued building and surprising the community. Some users are pointing to its potential, meme power and strong market positioning.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending following news of a $245 million defense contract, with community members discussing the potential for a short squeeze given the high short interest and comparing it to $MP's contract run. Investors are also anticipating further catalysts, including a potential DOD grant, and speculating about the company's growth prospects and potential acquisitions. The community sentiment is largely bullish, focusing on UAMY's strategic importance in securing a domestic antimony supply.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG.X is trending as the community rallies around recent developments, including a new partnership and upcoming fight sponsorship. The coin's reward system, which pays holders in Solana, is a key talking point, with many emphasizing its potential for long-term passive income. Despite some skepticism, community members express strong conviction in the project's potential and unique model.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates a major announcement and discusses potential partnerships, including speculation around Ripple and other institutional collaborations. Recent news highlights Zebec's advancements in real-time stablecoin payroll solutions and regulatory compliance, fueling optimism about its potential for growth and adoption. Some traders are focused on key support levels, while others are debating potential exchange listings and the timing of 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Shares of clinical-stage genetic medicine company Lexeo Therapeutics, Inc. soared over 50% on Monday, marking their best day on record. The rally extended into after-hours trading following the company's latest quarterly results, which largely pleased investors.Lexeo specializes in therapies for hereditary and acquired diseases, with a focus on genetically defined cardiovascular conditions and a subset of Alzheimer's disease.&nbsp;Its pipeline includes LX2006 for treating Friedreich's ataxia cardiomyopathy and LX1001 for APOE4 homozygous Alzheimer's patients.According to Stocktwits data, the company reported an adjusted fourth-quarter loss of $0.78 per share, beating expectations for a $0.81 loss. The early-stage biotech firm is still in a pre-revenue stage.CEO R. Nolan Townsend highlighted regulatory progress on LX2006, noting ongoing collaboration with the FDA for an accelerated approval pathway.&nbsp;He also announced promising early safety data for LX2020, a treatment for arrhythmogenic cardiomyopathy (PKP2-ACM).&nbsp;The company expects to share additional clinical updates later in 2025, with the second cohort of a Phase 1/2 trial now fully enrolled.Despite the stock's sharp rally, Leerink lowered its price target from $19 to $18, which still implies a potential fourfold gain from current levels.&nbsp;The research firm remains bullish, citing positive registrational design elements in the LX2006 pivotal trial and interim data for LX2020.Lexeo ended 2024 with $128.5 million in cash and investments, which management believes will sustain operations into 2027.On Stocktwits, Lexeo's following surged 13% — the largest jump among biotech stocks.&nbsp;The stock, however, remains down over 39% year-to-date, with short interest creeping up from 6.2% to 7.3%.Traders on Stocktwits are watching technical patterns closely.&nbsp;"Nice breakout. I could see this running for a while," one user noted.<stembedurl>https://stocktwits.com/Sillyspuh/message/609105298</stembedurl>Another speculated that a cup-and-handle formation was forming.<stembedurl>https://stocktwits.com/Marcobucks/message/609063542</stembedurl>According to Koyfin, seven Wall Street analysts cover Lexeo. Four rate it a 'buy,' while three assign a 'strong buy' or equivalent rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.  

Equity

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.  


Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ('Satellos' or the 'Company'), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data

Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene...

Buy Rating Affirmed for Lexeo Therapeutics Amid Promising Clinical Trial Results for FA-CM Treatment

Geulah Livshits, an analyst from Chardan Capital, reiterated the Buy rating on Lexeo Therapeutics, Inc. (LXEO Research Report). The associated pr...

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor...

Lexeo Therapeutics expects cash to fund operations into 2027

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lexeo Therapeutics reports Q4 EPS (86c), consensus (73c)

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.52	--	--	N/A
Q2 '25	-$0.68	-$0.60	11.68%	BEAT
Q1 '25	-$0.78	-$0.99	-26.38%	MISSED
Q4 '24	-$0.81	-$0.78	3.36%	BEAT
Q3 '24	-$0.68	-$0.89	-31.19%	MISSED

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest LXEO News

LXEO Lexeo Therapeutics Inc.